Clinical Trial: SABR PRIMER - A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937281) titled 'SABR PRIMER - A Phase II Trial Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors' on April 15.

Brief Summary: The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer.

Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy.

Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy.

The exploratory objective is to correlate toxicities and outcomes with peripheral blood bio...